Understanding tumor lysis syndrome

  • Lara ZafraniEmail author
  • Emmanuel Canet
  • Michael Darmon
Understanding the Disease
Tumor lysis syndrome (TLS) is a life-threatening condition in patients with extensive and chemosensitive malignancies. It usually occurs as a consequence of anticancer treatments, although it can also arise spontaneously (in up to a third of TLS cases) [ 1, 2]. TLS results from the rapid destruction of malignant cells, whose intracellular content (ions, proteins, and metabolites) is consequently released into the extracellular space. Potassium, calcium, phosphates, and deoxyribonucleic acid (DNA), which are present in high concentrations in malignant cells, are released into the extracellular space, leading to hyperkalemia, hyperphosphatemia, and subsequent hypocalcemia. DNA catabolism leads to the release of adenosine and guanosine, which are converted into xanthine and then uric acid. TLS occurs when renal clearance is insufficient to handle this metabolite release. The above-described metabolic disturbances may contribute to the development of acute kidney injury (AKI), thereby...


Compliance with ethical standards

Conflicts of interest

L Zafrani has received a research grant from Jazz Pharma. Dr. Darmon reports grants from MSD, personal fees from Gilead-Kite, personal fees from Astelas, outside the submitted work; Dr. CANET reports personal fees from GILEAD, outside the submitted work.


  1. 1.
    Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854CrossRefGoogle Scholar
  2. 2.
    Darmon M, Vincent F, Camous L et al (2013) Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol 162:489–497CrossRefGoogle Scholar
  3. 3.
    Soares M, Feres GA, Salluh JIF (2009) Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clin Sao Paulo Braz 64:479–481CrossRefGoogle Scholar
  4. 4.
    Canet E, Zafrani L, Lambert J et al (2013) Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS ONE 8:e55870CrossRefGoogle Scholar
  5. 5.
    Darmon M, Guichard I, Vincent F et al (2010) Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 51:221–227CrossRefGoogle Scholar
  6. 6.
    Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11CrossRefGoogle Scholar
  7. 7.
    Howard SC, Trifilio S, Gregory TK et al (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563–573CrossRefGoogle Scholar
  8. 8.
    Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586CrossRefGoogle Scholar
  9. 9.
    Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671CrossRefGoogle Scholar
  10. 10.
    Conger JD, Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59:786–793CrossRefGoogle Scholar
  11. 11.
    Cortes J, Moore JO, Maziarz RT et al (2010) Control of Plasma Uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213CrossRefGoogle Scholar
  12. 12.
    Feng X, Dong K, Pham D et al (2013) Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 38:301–308CrossRefGoogle Scholar
  13. 13.
    Boles JM, Dutel JL, Briere J et al (1984) Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53:2425–2429CrossRefGoogle Scholar
  14. 14.
    Kanfer A, Richet G, Roland J, Chatelet F (1979) Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma. Br Med J 1:1320–1321CrossRefGoogle Scholar
  15. 15.
    Agha-Razii M, Amyot SL, Pichette V et al (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 54:59–63Google Scholar
  16. 16.
    Mamez A-C, Raffoux E, Chevret S et al (2016) Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leuk Lymphoma 57:2281–2288CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medical Intensive Care Unit, Hopital Saint Louis, Assistance des Hôpitaux de ParisParis UniversityParisFrance
  2. 2.INSERM, UMR 976, Human Immunology Pathophysiology and ImmunotherapyHôpital Saint LouisParisFrance
  3. 3.Intensive Care UnitNantes University HospitalNantesFrance

Personalised recommendations